Stifel Financial Corp Trims Stock Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Stifel Financial Corp reduced its holdings in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 16.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 3,252 shares of the medical instruments supplier’s stock after selling 655 shares during the period. Stifel Financial Corp owned about 0.06% of Mesa Laboratories worth $422,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MLAB. Geneva Capital Management LLC increased its stake in Mesa Laboratories by 2.0% in the third quarter. Geneva Capital Management LLC now owns 191,976 shares of the medical instruments supplier’s stock worth $24,930,000 after purchasing an additional 3,732 shares during the period. Eagle Asset Management Inc. grew its holdings in shares of Mesa Laboratories by 10.9% in the third quarter. Eagle Asset Management Inc. now owns 165,955 shares of the medical instruments supplier’s stock worth $19,722,000 after purchasing an additional 16,293 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Mesa Laboratories by 7.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 131,891 shares of the medical instruments supplier’s stock worth $11,444,000 after buying an additional 8,722 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Mesa Laboratories by 38.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 62,609 shares of the medical instruments supplier’s stock valued at $8,130,000 after buying an additional 17,450 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its position in Mesa Laboratories by 21.8% in the 3rd quarter. Principal Financial Group Inc. now owns 35,107 shares of the medical instruments supplier’s stock valued at $4,559,000 after buying an additional 6,292 shares during the period. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on MLAB shares. StockNews.com lowered shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th. Evercore ISI raised their price objective on Mesa Laboratories from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st.

Insider Activity at Mesa Laboratories

In related news, CEO Gary M. Owens sold 2,518 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $113.62, for a total transaction of $286,095.16. Following the sale, the chief executive officer now owns 45,888 shares of the company’s stock, valued at $5,213,794.56. This trade represents a 5.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.40% of the stock is currently owned by corporate insiders.

Mesa Laboratories Stock Down 1.9 %

Shares of Mesa Laboratories stock opened at $133.06 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.70 and a quick ratio of 0.51. The stock has a market cap of $722.65 million, a price-to-earnings ratio of -2.92 and a beta of 0.86. The firm’s 50-day moving average is $120.61 and its two-hundred day moving average is $116.91. Mesa Laboratories, Inc. has a 1 year low of $83.68 and a 1 year high of $141.17.

Mesa Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 29th were paid a dividend of $0.16 per share. The ex-dividend date was Friday, November 29th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.48%. Mesa Laboratories’s dividend payout ratio is presently -1.40%.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.